Table 5. The course of C4 and albumin... | American Society of Hematology

Table 5.

The course of C4 and albumin serum levels in the studied patients after rituximab therapy

	Median value			Increase less than 25% or unchanged		Increase 25% or greater		Normalization		Notes
Months	0	+3	+6	+1 to +5	+6	+1 to +5	+6	+1 to +5	+6	—
C4 mg/dL	2	8^5-150	8^5-150	6 of 14	7 of 14	3 of 14	3 of 14	5 of 14	4 of 14	Normalized at month +6 in patients 3, 4, 14, 15
Albumin g/L	3.7	3.9^5-150	4.0^5-150	12 of 15	14 of 15	0 of 15	0 of 15	3 of 15	1 of 15	Normalized in patients 5 (+3 and +6) and 1, 11 (+3)

	Median value			Increase less than 25% or unchanged		Increase 25% or greater		Normalization		Notes
Months	0	+3	+6	+1 to +5	+6	+1 to +5	+6	+1 to +5	+6	—
C4 mg/dL	2	8^5-150	8^5-150	6 of 14	7 of 14	3 of 14	3 of 14	5 of 14	4 of 14	Normalized at month +6 in patients 3, 4, 14, 15
Albumin g/L	3.7	3.9^5-150	4.0^5-150	12 of 15	14 of 15	0 of 15	0 of 15	3 of 15	1 of 15	Normalized in patients 5 (+3 and +6) and 1, 11 (+3)

— indicates not applicable; C4, complement fraction (decreased if < 10 mg/dL); albumin, low at baseline (<3.5 g/L) in 4 of 15 patients (patients 1, 5, 8, and 11).

F5-150

P ≤ .05.

View Large

This Feature Is Available To Subscribers Only